Curis Updates Phase 1 Clinical Trial Results for Non-Hodgkin’s Lymphoma Treatment
On December 8, Curis, Inc. (CRIS) presented updated data on its Phase 1 clinical trial of CA-4948, an IRAK4 kinase inhibitor to treat patients with relapsed or refractory (R/R) non-Hodgkin’s lymphoma (NHL). The treatments was well tolerated by patients, and 6 out of 7 experienced anti-cancer activity marked by a decrease in tumor burden. As a result, Curis recommends a Phase 2 dosage of 300 mg twice daily for effective, long-term treatment in NHL patients. Curis is a biotechnology company focused on developing therapeutics for the treatment of cancer.
After detecting the event, Jet Equities issued an alert at 7:00 am. The next trade took place at 7:01 am for $1.65. The stock price continued to move higher throughout the day before closing at $6.55 with an event-day gain of 365%.
Curis held the gains from the announcement through the next four trading sessions. It closed on December 14 with a five-day gain of over 361%.
If you want to learn more about trading on clinical trial results, visit the Knowledge Center.
Subscribe here if you would like to start receiving these signals in real-time and start trading!